ExpressionEdits and Boehringer Ingelheim collaborate to enhance gene therapies
Boehringer will leverage ExpressionEdits’ Genetic Syntax Engine, a proprietary AI-powered platform that uses optimised introns to enhance gene expression without altering the underlying genetic sequence, for two gene therapy targets.
Gene therapies are often limited by low effectiveness due to insufficient expression of the therapeutic protein, leading to the need for high viral loads or repeated dosing.
ExpressionEdits has developed a novel approach to enhance therapeutic gene expression by restoring introns, called intronization.
The Babraham-based company – co-founded by serial life science entrepreneur Dr Allan Bradley – started life at The EpiCentre in Haverhill and is making great strides.
“We’re thrilled to announce our partnership with Boehringer Ingelheim,” said Dr Kärt Tomberg, CEO and Co-Founder, ExpressionEdits. “Our platform harnesses the potential of introns to overcome challenges in gene expression, enabling therapies that were previously limited by poor expression and narrow design options.
“Joining forces with the scientists at Boehringer Ingelheim will enable us to advance first-in-class gene therapies for patients with high medical need.”
The partnership expands ExpressionEdits’ intronization technology beyond protein-based therapeutics into the field of gene therapies.
The Genetic Syntax Engine supports gene therapy optimisation to boost potency and precision by creating in-cDNAs with optimal sites and introns, leading to increased protein production without altering core designs.
Boehringer Ingelheim will have access to this technology for undisclosed targets, allowing higher therapeutic protein yields at lower doses.
ExpressionEdits will receive undisclosed payments during the collaboration and is eligible to receive potential additional success based preclinical, clinical and commercial milestone-based payments. The company is committed to advancing genetic medicine through innovative research and development.
